摘要
目的研究三阴性乳腺癌(TNBC)组织中SETD2的表达情况及预后价值。方法收集蚌埠医学院第一附属医院2016年1月至2017年12月在肿瘤外科行手术治疗的90例TNBC患者组织及相应的癌旁组织蜡块行免疫组化,并收集2021年3月至10月在肿瘤外科进行乳腺癌改良根治术的20例患者标本,以上患者均为女性,进一步提取mRNA,通过qRT-PCR检测TNBC组织及癌旁正常组织中SETD2 mRNA的表达差异,免疫组化检测TNBC组织及癌旁正常组织中SETD2蛋白表达差异,并分析SETD2与TNBC临床病理学特征及预后的相关性。结果在癌组织中SETD2 mRNA、SETD2蛋白的表达量升高(P<0.001)。SETD2在TNBC中的表达量与肿瘤大小(P=0.008)、淋巴结转移(P=0.011)、TNM分期(P=0.028)相关。SETD2表达量与TNBC患者生存预后相关,且SETD2表达越高,患者生存率越低。结论SETD2在TNBC组织中高表达,并影响患者总体生存时间。提示SETD2可能是影响TNBC患者预后及治疗干预的潜在靶点。
Objective To investigate the expression and prognostic value of SETD2 in triple-negative breast cancer(TNBC)tissues.Methods A total of 90 cases of patients with TNBC in the First Affiliated Hospital of Bengbu Medical College from January 2016 to December 2017 were selected and immunohistochemical staining was performed on the tissues of TNBC patients and corresponding paracancerous tissues.20 cases of patients with TNBC who underwent modified radical mastectomy from March to October of 2021 were collected.All of the patients were female,and mRNA was extracted further.The difference of expression of SETD2 mRNA between TNBC tissues and adjacent normal tissues was detected by means of qRT-PCR.The expression of SETD2 protein in TNBC and adjacent normal tissues was detected by immunohistochemistry,and the correlation between SETD2 and clinicopathological features and prognosis of TNBC was analyzed.Results The mRNA and protein expressions of SETD2 increased in cancer tissues(P<0.001).The expression level of SETD2 in TNBC was correlated with tumor size(P=0.008),lymph node metastasis(P=0.011)and TNM stage(P=0.028).In addition,the expression level of SETD2 was correlated with the survival prognosis of TNBC patients,and the higher the expression of SETD2,the lower the patient survival rate.Conclusion SETD2 is highly expressed in TNBC tissues and affects the overall survival time of patients.These results suggest that SETD2 may be a potential target to affect the prognosis and therapeutic interv ention of TNBC patients.
作者
张立功
谢强
李志祥
张珂
ZHANG Ligong;XIE Qiang;LI Zhixiang;ZHANG Ke(Department of Tumor Surgery,the First Affiliated Hospital of Bengbu Medical College,Anhui Province,Bengbu 233000,China)
出处
《妇儿健康导刊》
2022年第7期114-117,F0003,共5页
JOURNAL OF WOMEN AND CHILDREN'S HEALTH GUIDE
基金
蚌埠医学院自然科学重点项目(BYKY2019102ZD)。
关键词
SETD2
三阴性乳腺癌
预后
SETD2
Triple-negative breast cancer
Prognosis
